These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 26755645)

  • 1. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
    Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
    Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
    Chung SS; Giehl N; Wu Y; Vadgama JV
    Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3.
    Fu Y; Xiong J
    Croat Med J; 2016 Oct; 57(5):457-464. PubMed ID: 27815936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation.
    Kim KW; Mutter RW; Cao C; Albert JM; Shinohara ET; Sekhar KR; Lu B
    Mol Cancer Ther; 2006 Nov; 5(11):2659-65. PubMed ID: 17121912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells.
    Papanikolaou V; Iliopoulos D; Dimou I; Dubos S; Kappas C; Kitsiou-Tzeli S; Tsezou A
    J Cell Mol Med; 2011 Jul; 15(7):1542-50. PubMed ID: 20716114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.
    Gritsko T; Williams A; Turkson J; Kaneko S; Bowman T; Huang M; Nam S; Eweis I; Diaz N; Sullivan D; Yoder S; Enkemann S; Eschrich S; Lee JH; Beam CA; Cheng J; Minton S; Muro-Cacho CA; Jove R
    Clin Cancer Res; 2006 Jan; 12(1):11-9. PubMed ID: 16397018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of potential Stat3-regulated genes in human breast cancer.
    Hsieh FC; Cheng G; Lin J
    Biochem Biophys Res Commun; 2005 Sep; 335(2):292-9. PubMed ID: 16081048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes.
    Papanikolaou V; Stefanou N; Dubos S; Papathanasiou I; Palianopoulou M; Valiakou V; Tsezou A
    Cell Oncol (Dordr); 2015 Apr; 38(2):155-64. PubMed ID: 25539992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
    He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
    PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
    De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
    Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDA-MB-453 breast cancer cells.
    Seo HS; Ku JM; Choi HS; Woo JK; Jang BH; Shin YC; Ko SG
    Anticancer Res; 2014 Jun; 34(6):2869-82. PubMed ID: 24922650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.